Scarica l'app Stockscreener
3.49
1.41%
-0.05
Pre-mercato:
3.45
-0.04
-1.15%
Precedente Chiudi:
$3.54
Aprire:
$3.54
Volume 24 ore:
44,925
Relative Volume:
0.71
Capitalizzazione di mercato:
$18.86M
Reddito:
$15.00M
Utile/perdita netta:
$2.71M
Rapporto P/E:
2.7426
EPS:
1.2725
Flusso di cassa netto:
$-2.89M
1 W Prestazione:
+1.45%
1M Prestazione:
-20.14%
6M Prestazione:
-16.31%
1 anno Prestazione:
-54.62%
Intervallo 1D:
$3.40
$3.57
Intervallo di 1 settimana:
$3.32
$3.7469
Portata 52W:
$3.19
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Nome
Neuphoria Therapeutics Inc
Settore
Industria
Telefono
781-439-5551
Indirizzo
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.49 | 18.86M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Reiterato | Maxim Group | Buy |
| 2022-01-10 | Iniziato | Berenberg | Buy |
| 2022-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Iniziato | Evercore ISI | Outperform |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Stocktwits
NEUP Q2 2026 Earnings: Significant EPS Beat Driven by Cost ManagementEarnings Cycle Report - dars.gov.et
NEUPNeuphoria Therapeutics Inc Latest SEC Filings - Finviz
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership - MSN
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer's Drug Trial Under Neuphoria Partnership - Mena FN
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms - Fierce Biotech
Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics - Moomoo
Neuphoria confirms merger talks with Scancell Holdings - Investing.com UK
Neuphoria confirms merger talks with Scancell Holdings By Investing.com - Investing.com Nigeria
Neuphoria Therapeutics (NEUP) Confirms Acquisition Talks with Sc - GuruFocus
Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85. - Bitget
Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell - TradingView
Neuphoria TherapeuticsConfirms Discussions - Moomoo
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewswire
Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP) - TradingView
Scancell in talks for reverse merger with Neuphoria Therapeutics - Investing.com
Scancell confirms advanced talks over reverse merger with Neuphoria - Proactive financial news
Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq - marketscreener.com
Scancell in talks for reverse merger with Neuphoria Therapeutics By Investing.com - Investing.com Canada
NEUP Forecast — Price Target — Prediction for 2027 - TradingView
Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria - marketscreener.com
Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NEUP Q1 2026 Earnings: EPS Surprise of 90.9% Signals Progress Amid Pre-Revenue StageEPS Revision Trend - dars.gov.et
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuphoria Therapeutics Inc (NEUP) Institutional Confidence - TradingKey
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuphoria Therapeutics Inc (NEUP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics Inc. (NEUP) Q1 2026 Earnings: EPS Surprise of 90.9% as Losses Narrow Significantly - DonanımHaber
Neuphoria Therapeutics (NEUP) Holds Near Support With Minimal Price MovementFundamental Weighted - Město Břeclav
NEUP Q1 2026 Earnings: Surprise EPS Beat Highlights Cost Discipline Despite Pre-Revenue StatusOne-Time Loss Impact - lwvtexas.org
Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings - TradingView
Neuphoria Therapeutics (NEUP) Registration filing Summary - Quartr
NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No RevenueBook Value Growth - The Legal Advocate
NEUP Q1 2026 Earnings: Significant EPS Beat Amidst Revenue AbsenceCapex Guidance - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower as Consolidation Continues Near SupportFlat Correction - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower Amid Consolidation Near SupportBollinger Band - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowed Loss Surprises as Pre-Revenue Stage ContinuesPreliminary Results - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowing Losses Beat Estimates Sharp, Yet Shares SlipRevenue Guidance Update - The Legal Advocate
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial - The Globe and Mail
Neuphoria Therapeutics (NEUP) Holds Steady Near Support – Can the Range Hold?Fibonacci Arc - newsline.com
Neuphoria Therapeutics (NEUP) Slips Amid Sector Headwinds – Key Support Levels in FocusSize Factor - The Legal Advocate
Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish BreakoutKey Reversal Day - Newser
Neuphoria Therapeutics Inc Azioni (NEUP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):